These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33527351)

  • 21. Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.
    Ursino M; Zohar S; Lentz F; Alberti C; Friede T; Stallard N; Comets E
    Biom J; 2017 Jul; 59(4):804-825. PubMed ID: 28321893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.
    Fernandes LL; Taylor JM; Murray S
    J Biopharm Stat; 2016; 26(3):475-98. PubMed ID: 26098782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing and evaluating dose-escalation studies made easy: The MoDEsT web app.
    Pallmann P; Wan F; Mander AP; Wheeler GM; Yap C; Clive S; Hampson LV; Jaki T
    Clin Trials; 2020 Apr; 17(2):147-156. PubMed ID: 31856600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hierarchical models for sharing information across populations in phase I dose-escalation studies.
    Cunanan KM; Koopmeiners JS
    Stat Methods Med Res; 2018 Nov; 27(11):3447-3459. PubMed ID: 28480828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.
    James GD; Symeonides SN; Marshall J; Young J; Clack G
    BMC Cancer; 2016 Aug; 16(1):703. PubMed ID: 27581751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
    Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
    Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies.
    Zheng W; Zhao Y; Lu Y; Miao H; Liu H
    J Biopharm Stat; 2016; 26(2):339-51. PubMed ID: 25629564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
    Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
    Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN-ET.
    Zhao Y; Liu R; Takeda K
    Pharm Stat; 2023; 22(3):440-460. PubMed ID: 36514849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
    Cunanan K; Koopmeiners JS
    BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
    Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
    Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology.
    Takeda K; Zhu J; Li R; Yamaguchi Y
    Pharm Stat; 2023; 22(6):1104-1115. PubMed ID: 37545018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.